Surgery Partners vs Tenet Healthcare
SGRY and THC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SGRY and THC compare
Tenet Healthcare is the larger company, worth 6.7 times as much as Surgery Partners ($23.3B against $3.5B).
Tenet Healthcare grew revenue faster over the last twelve months (6.2% versus 2.2% for Surgery Partners).
Tenet Healthcare scores higher on the StockData Score (13 against 5 for Surgery Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SGRY | THC |
|---|---|---|
| Size and price | ||
| Market cap | $3.5B | $23.3B |
| Share price | $26.66 | $292.97 |
| Change, 1 year | 66.3% | 50.5% |
| Change, 5 years | −44.9% | 278% |
| Beta (5Y) | 1.57 | 1.14 |
| Employees | 16K | 100K |
| StockData Score | ||
| Total score | 5 | 13 (better) |
| Valuation score | 2 | 5 (better) |
| Growth score | 0 | 3 (better) |
| Performance score | 1 | 1 |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 8.5× |
| P/S | 1.0× (better) | 1.1× |
| P/B | 2.1× (better) | 4.3× |
| EV/EBITDA | 13.7× | 5.7× (better) |
| P/FCF | 17.2× | 7.0× (better) |
| PEG | – | 0.14 |
| FCF yield | 5.8% | 14.3% (better) |
| Fair value | $25.32 | $458.44 |
| Margin of safety | −5.3% | 36.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 2.2% | 6.2% (better) |
| Revenue growth, 5Y average | 12.2% (better) | 3.9% |
| EPS growth (TTM) | – | 136% |
| EPS growth, 5Y average | – | 32.8% |
| Profitability | ||
| Operating margin | 10.8% | 24.4% (better) |
| Net margin | −2.6% | – |
| FCF margin | 6.0% | 15.0% (better) |
| Return on equity | −5.1% | – |
| Return on invested capital | 6.1% | 28.2% (better) |
| Financial health | ||
| Debt / equity | 1.84 (better) | 2.43 |
| Net debt / EBITDA | 4.99 | 1.68 (better) |
| Interest coverage | – | 6.6× |
| Current ratio | 2.17 (better) | 1.58 |
| Altman Z-score | 1.07 | 2.33 (better) |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Buyback yield | – | 7.8% |
| Shareholder yield | 0.00% | 7.8% (better) |
| Ownership | ||
| Held by institutions | 121% | 101% |
| Held by insiders | 85.9% | 0.97% |
| Insider net buying, 12 months | −$979K (better) | −$62.9M |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 48.6% | 2.3% |
Go deeper
- SGRY stock overview
- SGRY income statement
- SGRY valuation and score
- THC stock overview
- THC income statement
- THC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.